Bionor reports latent HIV reservoir reductions

Bionor Pharma ASA (OSE:BIONOR) said its Vacc-4x in combination with cancer drug Istodax romidepsin significantly reduced latent HIV reservoirs among patients in Part B of the Danish Phase I/II REDUC trial. Viral load remained below the limit of detection throughout the study in 11 of 17 evaluable patients.

Vacc-4x plus Istodax from Celgene Corp. (NASDAQ:CELG) significantly reduced the size of latent HIV reservoirs by 40% as measured by both total HIV DNA (p=0.012) and HIV quantitative viral outgrowth assay (qVOA) (p=0.019), meeting two of the study's three primary endpoints. ...